DiaMedica Therapeutics
DMAC
45 hedge funds and large institutions have $36.5M invested in DiaMedica Therapeutics in 2024 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 16 increasing their positions, 5 reducing their positions, and 5 closing their positions.
4,300% more call options, than puts
Call options by funds: $264K | Put options by funds: $6K
220% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 5
140% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 5
57% more capital invested
Capital invested by funds: $23.3M → $36.5M (+$13.2M)
13% more funds holding
Funds holding: 40 → 45 (+5)
2.68% more ownership
Funds ownership: 13.05% → 15.74% (+2.7%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.29M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$911K |
| 3 |
CLG
Cooperman Leon G
|
+$534K |
| 4 |
6CM
683 Capital Management
New York
|
+$359K |
| 5 |
Goldman Sachs
New York
|
+$325K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$107K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$51.7K |
| 3 |
PAS
Point72 Asia (Singapore)
Singapore
|
-$39.8K |
| 4 |
Simplex Trading
Chicago,
Illinois
|
-$17.3K |
| 5 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$13.7K |
DMAC Hedge Fund Activity: Q4 2024 in Review
45 of the 7,607 institutional investors tracked by Wall St. Rank reported a position in DiaMedica Therapeutics (DMAC) for Q4 2024, worth a combined $36.5M — up 57% from $23.3M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new DMAC positions and 5 closed out — a net gain of 7 holders — while 16 added to existing stakes and 5 trimmed.
The largest buyer was Susquehanna International Group, adding an estimated $1.29M. The largest seller was Morgan Stanley, cutting an estimated $107K.
- 45 institutional investors held DiaMedica Therapeutics (DMAC) as of Q4 2024, up from 40 in Q3 2024.
- Funds reported $36.5M of DiaMedica Therapeutics stock for Q4 2024, up 57% quarter-over-quarter.
- 12 funds opened new DiaMedica Therapeutics positions in Q4 2024 and 5 closed out, a net change of +7 holders.
- The largest DiaMedica Therapeutics buyer in Q4 2024 was Susquehanna International Group, an estimated $1.29M added.
- The largest DiaMedica Therapeutics seller in Q4 2024 was Morgan Stanley, an estimated $107K sold.
Based on aggregated 13F filings for Q4 2024.